Advances in asthma and COPD management: Delivering CFC-free inhaled therapy using Modulite® technology

Pulmonary Pharmacology and Therapeutics

Volumn 20, Issue 3, 2007, Pages 290-303

  Acerbi, D ^a   Brambilla, G ^a   Kottakis, I ^a  

^a CHIESI FARMACEUTICI S P A   (Italy)

Author keywords

Hydrofluoroalkane (HFA); Modulite ; Pressurized metered dose inhaler (pMDI)

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CHLOROFLUOROCARBON; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FLUORINATED HYDROCARBON; FLUTICASONE PROPIONATE; FORMOTEROL; FORMOTEROL FUMARATE; METHYLXANTHINE; SALBUTAMOL; SALMETEROL XINAFOATE;

AEROSOL; ARTICLE; ASTHMA; BRONCHUS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG FORMULARY; HUMAN; METERED DOSE INHALER; PARTICLE SIZE; PATHOPHYSIOLOGY; PATIENT; PATIENT ATTITUDE; PHYSICIAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ASTHMA; DRUG DELIVERY SYSTEMS; HUMANS; META-ANALYSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS; RESPIRATORY THERAPY;

EID: 33846999016     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2006.05.005     Document Type: Article

References (76)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Scientific Committee. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Pocket guide to COPD diagnosis, management and prevention. A Guide for Health Care Professionals 2003 (Updated 2004). Available at: www.goldcopd.com/
2. Global Initiative for Asthma. Pocket guide for asthma management and prevention (Updated 2004). Available at: www.ginasthma.com
3. Hurd S., and Pauwels R. Global initiat ive for chronic obstructive lung diseases (GOLD). Pulm Pharmacol Ther 15 4 (2002) 353-355
4. Bousquet J. Global initiative for asthma (GINA) and its objectives. Clin Exp Allergy 30 Suppl. 1 (2000) 2-5
5. British Thoracic Society; Scottish Intercollegiate Guidelines Network. British guidelines on the management of asthma. Thorax 58 Suppl. 1 (2003) i1-i94
6. National Collaborating Centre for Chronic Conditions. Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 59 Suppl. 1 (2004) 1-232
7. Ozone Secretariat United Nations Environment Programme. The Secretariat for The Vienna Convention for the Protection of the Ozone Layer & The Montreal Protocol on Substances that Deplete the Ozone Layer. The Montreal Protocol on Substances that Deplete the Ozone Layer 2000. Available at: www.unep.org/ozone/pdf/Montreal-Protocol2000.pdf
8. Zeidler M., and Corren J. Hydrofluoroalkane formulations of inhaled corticosteroids for the treatment of asthma. Treat Respir Med 3 1 (2004) 35-44
9. Ganderton D., Lewis D., Davies R., et al. Modulite: a means of designing the aerosols generated by pressurized metered dose inhalers. Respir Med 96 Suppl. D (2002) S3-S8
10. Acerbi D., Daley Yates P.T., Poli G., et al. Pharmacokinetics of a new CFC-free metered dose inhaler of beclomethasone dipropionate following multiple dosing in asthmatic patients. Resp Drug Deliv VIII 2 (2000) 395-398
11. Woodcock A., Acerbi D., and Poli G. Modulite technology: pharmacodynamic and pharmacokinetic implications. Respir Med 96 Suppl. D (2002) S9-S15
12. Brambilla G., Ganderton D., Garzia R., et al. Modulation of aerosol clouds produced by pressurised inhalation aerosols. Int J Pharm 186 1 (1999) 53-61
13. Ganderton D, Lewis D, Meakin B, et al. The modulation of clouds generated by pMDIs [abstract plus poster]. Presented at the 12th Biennial Congress of the International Society for Aerosols in Medicine (ISAM), Vienna, Austria, June 12-16, 1999.
14. McDonald K.J., and Martin G.P. Transition to CFC-free metered dose inhalers-into the new millennium. Int J Pharm 201 1 (2000) 89-107
15. Ganderton D., Lewis D., Davies R., et al. The formulation and evaluation of a CFC-free budesonide pressurised metered dose inhaler. Respir Med 97 Suppl. D (2003) S4-S9
16. Acerbi D., Deroubaix X., De Bruyn S., et al. Biopharmaceutical optimisation of a new CFC-free budesonide pMDI [abstract plus poster]. Respir Drug Deliv VIII (2002) 85-87
17. Bousquet J., and Cantini L. Clinical studies in asthmatics with a new non-extra fine HFA formulation of beclometasone dipropionate (BDP Modulite). Respir Med 96 Suppl. D (2002) S17-S27
18. Vastagh E., Kuna P., Calistruc P., et al. Efficacy and safety of inhaled budesonide delivered once or twice daily via HFA-134a in mild to moderate persistent asthma in adult patients. Comparison with budesonide CFC. Respir Med 97 Suppl. D (2003) S20-S28
19. Houghton C.M., Langley S.J., Singh S.D., et al. Comparison of bronchoprotective and bronchodilator effects of a single dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo-controlled, crossover study. Br J Clin Pharmacol 58 4 (2004) 359-366
20. ®: a simple solution to a difficult problem. Respiration 72 Suppl. 1 (2005) 3-5
21. Brambilla G, Davies RJ, Ferraris A, et al. Plume profiling of beclomethasone dipropionate pMDIs [abstract plus poster]. Presented at the 13th International Congress of the International Society for Aerosols in Medicine (ISAM), Interlaken, Switzerland, September 17-21, 2001.
22. Sommerer K. Airflow resistance of different inhalation devices and visualization of the aerosol plume emitted by different metered dose inhalers (2005), Inamed Research GmbH & Co., Hamburg, Germany
23. European Directorate for the Quality of Medicines. European pharmacopeia, 4th ed. Strasbourg, France, 2002.
24. Fink J.B. Metered-dose inhalers, dry powder inhalers, and transitions. Respir Care 45 6 (2000) 623-635
25. Usmani O.S., Biddiscombe M.F., Nightingale J.A., et al. Effects of bronchodilator particle size in asthmatic patients using monodisperse aerosols. J Appl Physiol 95 5 (2003) 2106-2112
26. Hickey A.J. Summary of common approaches to pharmaceutical aerosol administration. In: Hickey A.J. (Ed). Pharmaceutical inhalation aerosol technology (1992), Marcel Dekker, New York 255-288
27. Brand P., Meyer T., Haussermann S., et al. Optimum peripheral drug deposition in patients with cystic fibrosis. J Aerosol Med 18 1 (2005) 45-54
28. Stahlhofen W., Rudolf G., and James A.C. Intercomparison of experimental regional aerosol deposition data. J Aerosol Med 2 3 (1989) 285-308
29. Musante C.J., Schroeter J.D., Rosati J.A., et al. Factors affecting the deposition of inhaled porous drug particles. J Pharm Sci 91 7 (2002) 1590-1600
30. Acerbi D, Poli G, Haussermann S, et al. Lung deposition of formoterol HFA in healthy volunteers, asthmatic and COPD patients [abstract plus poster]. Presented at the European Respiratory Society Annual Congress (ERS), Copenhagen, Denmark, September 17-21, 2005.
31. Dolovich M., and Labiris R. Imaging drug delivery and drug responses in the lung. Proc Am Thorac Soc 1 (2004) 329-337
32. Meyer T., Brand P., Ehlich H., et al. Deposition of Foradil P in human lungs: comparison of in vitro and in vivo data. J Aerosol Med 17 1 (2004) 43-49
33. Labiris N.R., and Dolovich M.B. Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 56 6 (2003) 600-612
34. Labiris N.R., and Dolovich M.B. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 56 6 (2003) 588-599
35. Pritchard J.N. The influence of lung deposition on clinical response. J Aerosol Med 14 Suppl. 1 (2001) S19-S26
36. US Department of Health and Human Services. National Institutes of Health, National Heart, Lung, and Blood Institute, National Asthma Education and Prevention Program. Expert Panel Report: guidelines for the diagnosis and management of asthma. Update on selected topics 2002. NIH Publication No. 02-5074, June 2003. Available at: www.nhlbi.nih.gov/guidelines/asthma/asthupdt.htm
37. Roy S.R., and Milgrom H. Management of the acute exacerbation of asthma. J Asthma 40 6 (2003) 593-604
38. ® spacer: controlled clinical trial vs. the conventional CFC. Respir Med 96 10 (2002) 784-789
39. Anderson P.B., Langley S.J., Mooney P., et al. Equivalent efficacy and safety of a new HFA-134a formulation of BDP compared with the conventional CFC in adult asthmatics. J Invest Allergol Clin Immunol 12 2 (2002) 107-113
40. Woodcock A., Williams A., Batty L., et al. Effects on lung function, symptoms, and bronchial hyperreactivity of low-dose inhaled beclomethasone dipropionate given with HFA-134a or CFC propellant. J Aerosol Med 15 4 (2002) 407-414
41. Rocca-Serra J.P., Vicaut E., Lefrançois G., et al. Efficacy and tolerability of a new non-extrafine formulation of beclomethasone HFA-134a in patients with asthma. Clin Drug Invest 22 10 (2002) 653-665
42. Lee T.L., Adler L., McLaren G., et al. Assessment of efficacy and systemic safety of a new chlorofluorocarbon-free formulation of inhaled beclomethasone dipropionate in asthmatic children. Pediatr Allergy Immunol 15 3 (2002) 133-143
43. Acerbi D, Poli G, Nollevaux F. Comparative evaluation of HPA function after repeated treatment with BDP CFC or BDP HFA pMDIs. Pharmaceuticals Sciences Fair & Exhibition, Nice, France, 12-17 June, 2005.
44. Brambilla G, Church T, Ganderton D, et al. Budesonide 200 HFA Modulite™ Delivery from the Chiesi Jet™. Presented at the Nasal & Pulmonary Drug Delivery VII, Barcelona, Spain, September 15-17, 2003.
45. Grzelewska-Rzymowska I., Malolepszy J., de Molina M., et al. Equivalent asthma control and systemic safety of inhaled budesonide delivered via HFA-134a or CFC propellant in a broad range of doses. Respir Med 97 Suppl. D (2003) S10-S19
46. ®/Aerolizer™) and of placebo (pMDI or Aerolizer) in moderate to severe asthmatic patients. Respiration 72 Suppl. 1 (2005) 13-19
47. Bousquet J., Huchon G., Leclerc V., et al. A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients. Respiration 72 Suppl. 1 (2005) 6-12
48. Molimard M., Guenole E., Duvauchelle T., et al. A randomized, double-blind, double-dummy, safety crossover trial comparing cumulative doses up to 96 μg of formoterol delivered via an HFA-134a-propelled pMDI vs. same cumulative doses of formoterol DPI and placebo in asthmatic patients. Respiration 72 Suppl. 1 (2005) 28-34
49. Dusser D., Vicaut E., and Lefrançois G. Double-blind, double-dummy, multinational, multicenter, parallel-group design clinical trial of clinical non-inferiority of formoterol 12 μg/unit dose in a b.i.d. regimen administered via an HFA-propellant-pMDI or a dry powder inhaler in a 12-week treatment period of moderate to severe stable persistent asthma in adult patients. Respiration 72 Suppl. 1 (2005) 20-27
50. ®, FDP) associated with the Volumatic™ spacer in adults with mild to moderate persistent asthma [abstract plus poster]. Eur Respir J 22 Suppl. 45 (2003) 473s
51. Cheer S.M., and Scott L.J. Formoterol: a review of its use in chronic obstructive pulmonary disease. Am J Respir Med 1 4 (2002) 285-300
52. Bouros D., Bachlitzanakis N., Kottakis J., et al. Formoterol and beclomethasone versus higher dose beclomethasone as maintenance therapy in adult asthma. Eur Respir J 14 3 (1999) 627-632
53. Bateman E.D., Bantje T.A., Joao Gomes M., et al. Combination therapy with single inhaler budesonide/formoterol compared with high dose of fluticasone propionate alone in patients with moderate persistent asthma. Am J Respir Med 2 3 (2003) 275-281
54. Ind P.W., Haughney J., Price D., et al. Adjustable and fixed dosing with budesonide/formoterol via a single inhaler in asthma patients: the ASSURE study. Respir Med 98 5 (2004) 464-475
55. O'Byrne P.M., Bisgaard H., Godard P.P., et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 171 2 (2005) 129-136
56. Pohunek P., and Tal A. Budesonide and formoterol in a single inhaler controls asthma in adolescents. Int J Adolesc Med Health 16 2 (2004) 91-105
57. Remington T.L., Heaberlin A.M., and DiGiovine B. Combined budesonide/formoterol turbuhaler treatment of asthma. Ann Pharmacother 36 12 (2002) 1918-1928
58. Rosenhall L., Elvstrand A., Tilling B., et al. One-year safety and efficacy of budesonide/formoterol in a single inhaler (Symbicort Turbuhaler) for the treatment of asthma. Respir Med 97 6 (2003) 702-708
59. Ni Chroinin M, Greenstone IR, Ducharme FM. Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults. The Cochrane Database of Systematic Reviews 2004, Issue 4, Art. No. CD005307. Doi:10.1002/14651858.CD005307.
60. Chiesi Farmaceutici SpA, Data on File. 2004.
61. Reynolds N.A., Perry C.M., and Keating G.M. Budesonide/formoterol: in chronic obstructive pulmonary disease. Drugs 64 4 (2004) 431-441 discussion 433-4
62. Rabe K.F. State of the art in beta2-agonist therapy: a safety review of long-acting agents. Int J Clin Pract 57 8 (2003) 689-697
63. Szafranski W., Cukier A., Ramirez A., et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 21 1 (2003) 74-81
64. Agusti A.G. COPD, a multicomponent disease: implications for management. Respir Med 99 6 (2005) 670-682
65. Larj M.J., and Bleecker E.R. Therapeutic responses in asthma and COPD corticosteroids. Chest 126 2 Suppl. 1 (2004) 138S-149S discussion 159S-61S
66. Nannini L, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long acting beta-agonist in one inhaler for chronic obstructive pulmonary disease. The Cochrane Database of Systematic Reviews 2004, Issue 3, Art. No. CD003794. Doi:10.1002/14651858.CD003794.pub2
67. Cazzola M., Santus P., Di Marco F., et al. Onset of action of formoterol/budesonide in single inhaler vs. formoterol in patients with COPD. Pulm Pharmacol Ther 17 3 (2004) 121-125
68. Barnes P.J. Therapy of chronic obstructive pulmonary disease. Pharmacol Ther 97 1 (2003) 87-94
69. Cazzola M., Santus P., Di Marco F., et al. Bronchodilator effect of an inhaled combination therapy with salmeterol+fluticasone and formoterol+budesonide in patients with COPD. Respir Med 97 5 (2003) 453-457
70. Burge S. Should inhaled corticosteroids be used in the long term treatment of chronic obstructive pulmonary disease?. Drugs 61 11 (2001) 1535-1544
71. Pauwels R.A., Buist A.S., Calverley P.M., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop Summary. Am J Respir Crit Care Med 163 5 (2001) 1256-1276
72. European Agency for the Evaluation of Medicinal Products: Committee for Proprietary Medicinal Products Meeting of 21-23 January 2003. Press Release, 2003. Available at: http://www.emea.eu.int/pdfs/human/press/pr/029403en.pdf
73. Medford A.R. Combination therapy with maintenance budesonide and formoterol in COPD. Eur Respir J 24 6 (2004) 1070 author reply 1070-1
74. Adjei A., and Garren J. Pulmonary delivery of peptide drugs: effect of particle size on bioavailability of leuprolide acetate in healthy male volunteers. Pharm Res 7 6 (1990) 565-569
75. Farr S.J., McElduff A., Mather L.E., et al. Pulmonary insulin administration using the AERx system: physiological and physicochemical factors influencing insulin effectiveness in healthy fasting subjects. Diabetes Technol Ther 2 2 (2000) 185-197
76. Gonda I. The ascent of pulmonary drug delivery. J Pharm Sci 89 7 (2000) 940-945